David Watson's most recent trade in AMKOR Technology Inc. was a trade of 2 Restricted Stock Units done . Disclosure was reported to the exchange on June 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2026 | 2 | 2,615 | - | - | Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 651.22 per share. | 15 Jun 2026 | 9,993 | 40,005 (0%) | 0% | 651.2 | 6,507,641 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 707.35 per share. | 15 Jun 2026 | 1,880 | 40,005 (0%) | 0% | 707.4 | 1,329,818 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 1,666 | 4,415 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 1,000 | 3,415 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.47 per share. | 15 Jun 2026 | 862 | 40,867 (0%) | 0% | 39.5 | 34,023 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 667 | 2,748 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 15 Jun 2026 | 588 | 41,455 (0%) | 0% | 61.2 | 35,997 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 148.72 per share. | 15 Jun 2026 | 430 | 41,885 (0%) | 0% | 148.7 | 63,950 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | 14 May 2026 | 144,517 | 0 (0%) | 0% | - | Common Stock | ||
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 82,500 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 55,986 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 55,986 | 55,986 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 55,986 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 50,974 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | 14 May 2026 | 50,136 | 0 (0%) | 0% | - | Common Stock | ||
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 41,250 | 41,250 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 41,250 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 38,250 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 37,708 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 34,533 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 32,072 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 28,508 | 28,508 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 28,508 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 27,993 | 27,993 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 27,993 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 14,000 | 0 | - | - | Stock Option (right to buy) | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 11,874 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | 14 May 2026 | 10,000 | 0 (0%) | 0% | - | Common Stock | ||
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 7,363 | 0 (0%) | 0% | - | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 May 2026 | 6,001 | 0 (0%) | 0% | - | Common Stock | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2026 | 9,893 | 0 | - | - | Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2026 | 9,893 | 130,650 (0%) | 0% | 0 | Common Stock | |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2026 | 2,613 | 2,613 | - | - | Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 602.11 per share. | 16 Apr 2026 | 19,310 | 49,998 (0%) | 0% | 602.1 | 11,626,744 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 11,513 | 63,552 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 10,000 | 18,839 | - | - | Earnings Per Share Performance-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 5,756 | 69,308 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 5,000 | 7,284 | - | - | Performance-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 4,000 | 6,252 | - | - | Time-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 3,333 | 11,585 | - | - | Time-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 2,302 | 52,039 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 1,869 | 49,001 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 1,333 | 10,252 | - | - | Time-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 736 | 49,737 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 3,339 | 28,839 | - | - | Earnings Per Share Performance-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 415 | 6,081 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 284 | 12,284 | - | - | Performance-Based Restricted Stock Units | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 251 | 14,918 | - | - | Time-Based Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 18 | 9,893 | - | - | Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.66 per share. | 25 Feb 2026 | 20,000 | 122,980 (0%) | 0% | 5.7 | 113,200 | Common Stock |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2026 | 20,000 | 0 | - | - | Director Stock Option (Right-to-Buy) | |
| AMKOR Tech Inc | David N. Watson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 25 Feb 2026 | 2,223 | 120,757 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2026 | 55,986 | 144,517 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 21.77 per share. | 22 Jan 2026 | 7,832 | 88,531 (0%) | 0% | 21.8 | 170,467 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 19.79 per share. | 20 Jan 2026 | 2,475 | 96,363 (0%) | 0% | 19.8 | 48,987 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 22.19 per share. | 13 Jan 2026 | 5,780 | 98,838 (0%) | 0% | 22.2 | 128,242 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.95 per share. | 07 Jan 2026 | 888 | 104,618 (0%) | 0% | 15.0 | 13,276 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 888 | 14,000 | - | - | Stock Option (Right to Buy) | |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2025 | 20 | 9,874 | - | - | Restricted Stock Units | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 24.49 per share. | 16 Dec 2025 | 5,000 | 103,730 (0%) | 0% | 24.5 | 122,450 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 20.06 per share. | 17 Nov 2025 | 5,000 | 108,730 (0%) | 0% | 20.1 | 100,300 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 25.22 per share. | 16 Oct 2025 | 5,000 | 113,730 (0%) | 0% | 25.2 | 126,100 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 277.01 per share. | 09 Oct 2025 | 4,441 | 47,691 (0%) | 0% | 277.0 | 1,230,201 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2025 | 559 | 559 (0%) | 0% | 0 | Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 272.27 per share. | 09 Oct 2025 | 559 | 0 (0%) | 0% | 272.3 | 152,199 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Oct 2025 | 559 | 47,132 (0%) | 0% | 0 | Common Stock | |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2025 | 27 | 9,854 | - | - | Restricted Stock Units | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 24.34 per share. | 16 Sep 2025 | 5,000 | 118,730 (0%) | 0% | 24.3 | 121,700 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 10 Sep 2025 | 20,000 | 50,136 (0%) | 0% | 26.2 | 523,400 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 27.80 per share. | 18 Aug 2025 | 5,000 | 123,730 (0%) | 0% | 27.8 | 139,000 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 19.55 per share. | 16 Jul 2025 | 5,000 | 128,730 (0%) | 0% | 19.6 | 97,750 | Common Stock |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2025 | 38 | 9,827 | - | - | Restricted Stock Units | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 18.77 per share. | 16 Jun 2025 | 5,000 | 133,730 (0%) | 0% | 18.8 | 93,850 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 211.02 per share. | 09 Jun 2025 | 17,969 | 52,132 (0%) | 0% | 211.0 | 3,791,818 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 3,334 | 6,666 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 3,334 | 10,000 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 230.38 per share. | 09 Jun 2025 | 2,031 | 70,101 (0%) | 0% | 230.4 | 467,902 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.78 per share. | 09 Jun 2025 | 1,553 | 70,189 (0%) | 0% | 36.8 | 57,119 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.47 per share. | 09 Jun 2025 | 1,533 | 71,722 (0%) | 0% | 39.5 | 60,508 | Common Stock |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,000 | 5,666 | - | - | Option to Purchase Common Stock | |
| Argan Inc | David H. Watson | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 09 Jun 2025 | 410 | 72,132 (0%) | 0% | 61.2 | 25,100 | Common Stock |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 9,789 | 9,789 | - | - | Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 6,017 | 102,980 (0%) | 0% | 0 | Common Stock | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 6,017 | 0 | - | - | Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2025 | 25 | 6,017 | - | - | Restricted Stock Units | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 20,000 | 0 | - | - | Director Stock Option (Right-to-Buy) | |
| AMKOR Tech Inc | David N. Watson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.81 per share. | 14 Mar 2025 | 20,000 | 96,963 (0%) | 0% | 6.8 | 136,200 | Common Stock |
| Apellis Pharma Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Mar 2025 | 6,667 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Mar 2025 | 6,667 | 0 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharma Inc | David Watson | General Counsel | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 04 Mar 2025 | 5,569 | 138,730 (0%) | 0% | 25.1 | 139,789 | Common Stock |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 3,124 | 3,124 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 1,007 | 1,989 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 1,007 | 4,755 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 909 | 881 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 909 | 4,022 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 831 | 0 | - | - | Restricted Stock Units | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 831 | 3,346 (0%) | 0% | 0 | Common Stock | |
| Reynolds Consumer Products Inc | Clyde David Watson | Chief Legal Counsel/Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.61 per share. | 01 Feb 2025 | 326 | 4,429 (0%) | 0% | 27.6 | 9,001 | Common Stock |